Evidence map›Paper›PMID 27741524›Full record

ArticleOncotarget2016

Low Ki67/high ATM protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer.

Xiaolan Feng, Haocheng Li, Elizabeth N Kornaga, Michelle Dean, Susan P Lees-Miller, Karl Riabowol, Anthony M Magliocco, Don Morris, Peter H Watson, Emeka K Enwere and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Xiaolan FengDepartment of Oncology, BC Cancer Agency-Vancouver Island Center, Victoria, British Columbia, Canada.
Haocheng LiDepartment of Oncology, Tom Baker Cancer Centre and University of Calgary, Cumming School of Medicine, Calgary, Alberta, Canada.
Elizabeth N KornagaFunctional Tissue Imaging Unit, Translational Research Laboratory, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Michelle DeanFunctional Tissue Imaging Unit, Translational Research Laboratory, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Susan P Lees-MillerDepartment of Biochemistry and Molecular Biology, Health Science Building, University of Calgary, Alberta, Canada.
Karl RiabowolDepartment of Biochemistry and Molecular Biology, Health Science Building, University of Calgary, Alberta, Canada.
Anthony M MaglioccoDepartment of Anatomic Pathology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Don MorrisDepartment of Oncology, Tom Baker Cancer Centre and University of Calgary, Cumming School of Medicine, Calgary, Alberta, Canada.
Peter H WatsonDepartment of Pathology, BC Cancer Agency-Vancouver Island Center, Victoria, British Columbia, Canada.
Emeka K EnwereFunctional Tissue Imaging Unit, Translational Research Laboratory, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Gwyn BebbDepartment of Oncology, Tom Baker Cancer Centre and University of Calgary, Cumming School of Medicine, Calgary, Alberta, Canada.
Alexander PatersonDepartment of Oncology, Tom Baker Cancer Centre and University of Calgary, Cumming School of Medicine, Calgary, Alberta, Canada.
University of Calgary · CABC Cancer Agency · CAMoffitt Cancer Center · USUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study was designed to investigate the combined influence of ATM and Ki67 on clinical outcome in early stage hormone receptor positive breast cancer (ES-HPBC), particularly in patients with smaller tumors (< 4 cm) and fewer than four positive lymph nodes.

methods532 formalin-fixed paraffin-embedded specimens of resected primary breast tumors were used to construct a tissue microarray. Samples from 297 patients were suitable for final statistical analysis. We detected ATM and Ki67 proteins using fluorescence and brightfield immunohistochemistry respectively, and quantified their expression with digital image analysis. Data on expression levels were subsequently correlated with clinical outcome.

resultsRemarkably, ATM expression was useful to stratify the low Ki67 group into subgroups with better or poorer prognosis. Specifically, in the low Ki67 subgroup defined as having smaller tumors and no positive nodes, patients with high ATM expression showed better outcome than those with low ATM, with estimated survival rates of 96% and 89% respectively at 15 years follow up (p = 0.04). Similarly, low-Ki67 patients with smaller tumors, 1-3 positive nodes and high ATM also had significantly better outcomes than their low ATM counterparts, with estimated survival rates of 88% and 46% respectively (p = 0.03) at 15 years follow up. Multivariable analysis indicated that the combination of high ATM and low Ki67 is prognostic of improved survival, independent of tumor size, grade, and lymph node status (p = 0.02).

conclusionsThese data suggest that the prognostic value of Ki67 can be improved by analyzing ATM expression in ES-HPBC.

Indexed as

AdultAgedAged, 80 and overAtaxia Telangiectasia Mutated ProteinsBreast NeoplasmsFemaleHumansKi-67 AntigenMiddle AgedPrognosisReceptors, EstrogenReceptors, ProgesteroneRetrospective StudiesAtaxia Telangiectasia Mutated ProteinsATM protein, humanKi-67 AntigenReceptors, EstrogenReceptors, ProgesteroneATMautomated quantitative immunofluorescence analysisdisease specific overall survivalearly stage hormone receptor positive breast cancerKi67

Identifiers

PMID27741524
PMCPMC5349875
OpenAlexW2531765696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.